iGMDRD221
Canonical SMILES: CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
InChI: InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
InChI Key: NKANXQFJJICGDU-QPLCGJKRSA-N
Drug Class:
Anti-EstrogensAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic and Immunomodulating AgentsBCRP/ABCG2 SubstratesBenzene DerivativesBenzylidene CompoundsBone Density Conservation AgentsCardiotoxic antineoplastic agentsCytochrome P-450 CYP2C8 InhibitorsCytochrome P-450 CYP2C8 Inhibitors (moderate)Cytochrome P-450 CYP2D6 SubstratesCytochrome P-450 CYP3A SubstratesCytochrome P-450 CYP3A4 SubstratesCytochrome P-450 CYP3A5 SubstratesCytochrome P-450 CYP3A7 SubstratesCytochrome P-450 Enzyme InducersCytochrome P-450 Enzyme InhibitorsEndocrine TherapyEstrogen Agonist/AntagonistEstrogen AntagonistsEstrogen Receptor ModulatorsHormone AntagonistsHormone Antagonists and Related AgentsHormones, Hormone Substitutes, and Hormone AntagonistsHydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicP-glycoprotein/ABCB1 InducersP-glycoprotein/ABCB1 InhibitorsP-glycoprotein/ABCB1 SubstratesPotential QTc-Prolonging AgentsQTc Prolonging AgentsSelective Estrogen Receptor ModulatorsStilbenesDrug Targets:
ERESR1 (P03372)ESR2 (Q92731)EBP (Q15125)PRKCA (P17252)AR (P10275)KCNH2 (Q12809)NR1I2 (O75469)ESRRG (P62508)SHBG (P04278)Drug Pathways:
Estrogen signaling pathwayPathways in cancerHormone-relatedDrug metabolism - cytochrome P450Drug-model tissue-cancer distribution: Bubble Plot
Drug-gene pathway enrichments
Drug-gene GO enrichments
Drug-Gene: Aster Plot
Gene in drug-gene network: Network Plot

Models in Tamoxifen
Loading, please wait...
Model | Level | Reference ID | Tissue | Cancer | Drug | Clinical Response | Source | |
---|---|---|---|---|---|---|---|---|
No matching records found |